Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: aurora kinase inhibitors - SuperGen

Next Previous
X
Search
Drug Profile

Research programme: aurora kinase inhibitors - SuperGen

Alternative Names: MP 529 series; MP-529

Latest Information Update: 26 Sep 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Apr 2008 Pharmacokinetics and adverse events data from a Preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 06 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the Cancer pharmacodynamics section
  • 05 Apr 2006 Montigen has been acquired and merged into SuperGen

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top